PAP
EDSA icon

Persistent Asset Partners’s Edesa Biotech EDSA Stock Holding History

Persistent Asset Partners’s Portfolio EDSA Stock Details EDSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,319
Closed -$17.5K – 372
2025
Q4 		$17.5K Buy
+12,319
New +$24.1K 0.01% 317

Other funds holding EDSA

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

Persistent Asset Partners's EDSA Position: Q1 2026 in Review

Persistent Asset Partners sold out of Edesa Biotech (EDSA) in Q1 2026, closing a stake of 12,319 shares — an estimated $17.5K sold.

Persistent Asset Partners first reported a position in EDSA in Q4 2025 and held it in 1 quarter. The position peaked at $17.5K in Q4 2025. 28 funds tracked by Wall St. Rank hold EDSA as of Q1 2026.

  • Persistent Asset Partners reported no remaining Edesa Biotech position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 12,319 Edesa Biotech shares in Q1 2026, an estimated $17.5K.
  • Persistent Asset Partners first reported a position in Edesa Biotech in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Edesa Biotech position peaked at $17.5K in Q4 2025.
  • 28 funds tracked by Wall St. Rank held Edesa Biotech as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.